Prelude Therapeutics Inc

PRLD Nasdaq SEC CIK 1678660
Follow Prelude Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $5.6M −13.1% vs same quarter last year
Net income −$12.5M +36.4% vs same quarter last year
EPS, diluted −$0.12 +53.8% vs same quarter last year
Operating cash flow −$13.8M +27.9% vs same quarter last year
Revenue by quarter
$4M
$0
$0
$6.5M
$5.6M
$4.6M
$5.7M
$5.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$99.5M
FY24−$127.2M
FY23−$121.8M
FY22−$115.4M
FY21−$111.7M
FY20−$56.9M
FY19−$27.6M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$56.4M
FY24−$103.7M
FY23−$110.6M
FY22−$86.7M
FY21−$85.9M
FY20−$46.8M
FY19−$26.4M
FY18-